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Abstract 
Body fluids are a rich source of extracellular vesicles (EVs), which carry cargo derived from the secreting cells. 
So far, biomarkers for pathological conditions have been mainly searched from their protein, (mi)RNA, DNA 
and lipid cargo. Here, we explored the small molecule metabolites from urinary and platelet EVs relative to 
their matched source samples. As a proof-of-concept study of intra-EV metabolites, we compared alternative 
normalization methods to profile urinary EVs from prostate cancer patients before and after prostatectomy 
and from healthy controls.  
Methods: We employed targeted ultra-performance liquid chromatography-tandem mass spectrometry to 
profile over 100 metabolites in the isolated EVs, original urine samples and platelets. We determined the 
enrichment of the metabolites in the EVs and analyzed their subcellular origin, pathways and relevant enzymes 
or transporters through data base searches. EV- and urine-derived factors and ratios between metabolites 
were tested for normalization of the metabolomics data.  
Results: Approximately 1 x 1010 EVs were sufficient for detection of metabolite profiles from EVs. The profiles 
of the urinary and platelet EVs overlapped with each other and with those of the source materials, but they 
also contained unique metabolites. The EVs enriched a selection of cytosolic metabolites including members 
from the nucleotide and spermidine pathways, which linked to a number of EV-resident enzymes or 
transporters. Analysis of the urinary EVs from the patients indicated that the levels of glucuronate, D-ribose 
5-phosphate and isobutyryl-L-carnitine were 2–26-fold lower in all pre-prostatectomy samples compared to 
the healthy control and post-prostatectomy samples (p < 0.05). These changes were only detected from EVs 
by normalization to EV-derived factors or with metabolite ratios, and not from the original urine samples. 
Conclusions: Our results suggest that metabolite analysis of EVs from different samples is feasible using a 
high-throughput platform and relatively small amount of sample material. With the knowledge about the 
specific enrichment of metabolites and normalization methods, EV metabolomics could be used to gain novel 
biomarker data not revealed by the analysis of the original EV source materials. 










Extracellular vesicles (EVs) are known as a 
promising source of biomarkers. Many studies, 
particularly the ones addressing cancer, have focused 
on the RNA and protein cargo of EVs. Some 
EV-derived cancer biomarkers have already been 
transferred to clinical use [1, 2]. There are also new 
developments in the analysis of lipids [3], DNA [4, 5] 
and glycoproteomic profiles [6, 7]. Small molecule 
metabolites have attracted far less attention, although 
their analysis holds the potential to reveal dynamic 
changes in the metabolism downstream of genetic and 
proteomic regulation [8-11]. Since cancer cells tend to 
secrete more vesicles than normal cells [12, 13], 
exploration of the metabolite content of EVs in the 
body fluids could offer a sensitive and non-invasive 
method to detect dynamic cancer-related biomarkers.  
Metabolism of cancer cells is altered in several 
ways due to active cell proliferation i.e. the need for 
building blocks and energy. Hallmarks of cancer 
metabolism include accelerated glycolysis and lactic 
acid production—the Warburg’s effect—and 
upregulation of nucleotide synthesis, which are 
linked to the activation of transcription factors such as 
HIF1α and MYC [14]. Metabolite levels change 
accordingly, for example the Warburg’s effect and the 
activity of several nicotinamide adenine dinucleotide 
(NAD+) consuming enzymes lead to a low 
NAD+/NADH balance in cancer cells [15]. Prostate 
cancer (Pca) exhibits some characteristic alterations, 
such as the tendency to accumulate choline [16, 17], 
which has laid the foundation for choline C-11 
positron emission tomography (PET) scans to monitor 
Pca. Malignant transformation of prostate cells has 
also been reported to lead to a loss of the capability to 
accumulate zinc and citrate [18]. Lipid and amino acid 
metabolism are changed in the Pca tissues, which 
correlates with the overexpression of biosynthetic or 
catabolic enzymes such as alpha-methylacyl-CoA 
racemase (AMACR) involved in the beta-oxidation of 
fatty acids [19-21]. Interestingly, recent reports have 
revealed that the intra-exosomal metabolome also 
changes in cancer. Exosomes from cancer associated 
fibroblasts were shown to supply amino acids and 
increase glycolysis in cultured Pca cells [8]. In 
addition, EV metabolites from pancreatic cancer cell 
lines and plasma of endometrioid adenocarcinoma 
patients differed from the healthy control EVs [10]. 
Thus, EVs seem to play an important role in the 
metabolic control of prostate and other cancer cells.  
Despite these advances, normalization of EV 
biomarker data is generally a big challenge [22]. Due 
to the lack of standardized normalization methods, 
researchers studying urinary or other EVs have used 
creatinine and urine flow rate, EV-derived factors 
such as particle number or EV-enriched protein 
markers for normalization [23-26]. However, without 
comparative studies utilizing several normalization 
methods to the same data set, it cannot be concluded, 
which of the methods best brings out the differences.  
Since it is still largely unknown, what 
metabolites EVs contain, we profiled over hundred 
polar metabolites in the urinary EVs (uEVs) and EVs 
from another body fluid, i.e. platelet EVs (pEVs) from 
plasma, and in the matched original EV source 
materials, to characterize the enrichment, cellular 
pathways/locations and linked enzymes or 
transporters of the EV-metabolites. To evaluate the 
feasibility of the EV metabolomics for future 
biomarker discovery, we compared uEV samples 
from Pca patients before and after prostatectomy and 
from healthy controls utilizing several different 
normalization methods. Our results suggest that EVs 
enrich a selection of metabolites from the cytoplasm 
and that metabolomics of EVs could offer new kind of 
disease profiles not revealed by the conventional 
analysis of the original urine samples.  
Materials and Methods 
Ethical Approvals, Samples and Clinical 
Measurements  
Prostate cancer patient samples were obtained 
from patients participating with informed consent in 
the Helsinki Urological Biobank (HUB) project (Dnro 
263/13/03/02/2011; 379/13/03/02/2012 and Dnro § 
212), where the pathological stage and Gleason score 
were confirmed from the prostatectomy samples after 
prostatectomy. Patient details are given in Table 1 and 
Table S1. Mid-stream spot urine samples were 
collected according to standard operation procedures 
of the HUB i.e. after collection, the urine samples were 
kept cold and centrifuged at 1800 g for 10 min at +4°C. 
The supernatants were frozen and stored in liquid 
nitrogen vapor phase. Control samples from healthy < 
35 year-old men (Table 1 and S1) were processed 
similarly to the patient samples. Urine samples and 
matched plasma samples were collected 0–3 days 
before and 5–6 weeks after the prostatectomy. 
Creatinine values in the matched urine and plasma 
samples were measured in Helsinki-Uusimaa Central 
Hospital to ascertain that the donors did not have a 
kidney defect affecting the composition of urine and 
hence, the urinary EV pool. In each case, the creatinine 
levels indicated normal functioning of the kidneys. 
Prostate specific antigen (PSA) values were measured 
1–6 months before and 5–6 weeks (Table 1 and S1) and 
> 2 years (Table S1) after the prostatectomy. PSA 
values from controls were measured > 3 years after 





urine collection for the metabolomics analysis (Table 
S1). For the isolation of platelet-derived EVs, platelet 
concentrates (containing some residual plasma from 
the platelet isolation) from the Finnish Red Cross 
Blood Service (Dnro 235/13/03/00/2011) were 
obtained from four healthy donors with their 
informed consent and pooled.  
Isolation of EVs and Platelets 
EVs were isolated using differential 
centrifugation from individual frozen cell-free urine 
samples prepared by HUB as previously described 
[27]. The urine samples (Table 1) with higher volumes 
were processed without dilution, whereas one low 
volume sample (10 ml), the post-prostatectomy 
sample of patient HUB.1, was processed with the 
KeepEX protocol [27] i.e. dilution with alkaline buffer 
(Tris-HCl, pH 8.6) in order to maximize the EV yield. 
The procedure after this was the same for all the 
samples: vortexing, centrifugation at 8000 g for 15 
min, filtration (1.2 µm) and finally ultracentrifugation 
at 100 000 g for 90 min, with a repetition to wash the 
samples with 30 ml of PBS, all at +4°C. Supernatants 
were carefully removed by wiping the tube walls with 
cotton swabs to prevent the contamination of the EV 
pellet with any supernatant metabolites. Platelets 
were removed from 50 ml of the concentrate by four 
consecutive centrifugations at 1600 g for 20 min at RT 
without break, every time omitting the two ml 
overlaying the cell pellet to prevent transfer of 
platelets into the supernatant. The number of platelets 
after the last centrifugation was analyzed with 
Beckmann Coulter counter T-540 to be less than 2 x 
106/ml. The supernatant (40 ml) was diluted with PBS 
1:2 and centrifuged 110 000 g for 1 h 15 min at +4°C 
with type 50.2 Ti rotor (Beckman Coulter). The 
supernatant was removed and each pellet (from 10 ml 
of the platelet concentrate) was suspended to 16 ml 
PBS and re-centrifuged. Supernatant was carefully 
removed. All the EV samples were suspended in PBS 
and stored in protein LowBind tubes (Eppendorf) at 
-80°C. Platelets for metabolomics (10 x 106 platelets 
per sample from the same concentrate used for EV 
isolation) were pelleted at 1600 g for 20 min at RT, and 
washed with PBS followed by quick rinsing of the 
pellet with water. Pellets were immediately frozen 
with liquid nitrogen and stored at -80°C.  
Western Blotting 
Western blotting was performed as described 
[27]. For detection, x-ray film (Ultra Cruz™ 
Autoradiography Film, Santa Cruz Biotechnology 
(SC), Dallas, TX, USA) or, alternatively, Odyssey 
infrared scanner (LI-COR® Biosciences Ltd., 
Cambridge, UK) were used. To quantify the EVs for 
the metabolomics study (Fig. 2A), EVs from equal 
volumes of urine were loaded to gels. The CD9 bands 
were quantified by Image J [28]. Proteins from 
samples depicting the purification process (Fig. 1G, 
1800 g and 8000 g urine supernatant and filtrate 
samples), were extracted with ProteoSpin™ Urine 
Protein Concentration Micro Kit (Norgen Biotek 
Corp., Ontario, Canada). Protein concentrations were 
measured with BradfordUltra reagent (Expedeon) 
and 2 µg of protein loaded to gels from all purification 
process samples (Fig. 1G) and 20 µg of LNCaP cell 
lysate control. Platelet EVs and platelets from equal 
volumes of metabolomics samples were loaded to gels 
(Fig. S1).  
 
Table 1. Clinical and pathological information from the prostate cancer patients and controls, and analysis of the 
isolated urinary EVs. The table shows the Gleason score, pathological stage and proportion of the tumor area in the prostatectomy 
tissue sections, prostate specific antigen (PSA) concentration in the serum and creatinine values in the matched urine and plasma samples 
derived from the prostate cancer patients of the Helsinki Urological Biobank project (HUB.1–3). The quantity of EVs isolated from urine 
was determined by nanoparticle tracking analysis and western blotting of CD9 and expressed relative to urine volume. The table further 
shows the volume of urine used for urinary EV isolation, the number of urinary EVs subjected to metabolomics analysis and the number 










Figure 1. Validation of EV sample quality. A. Electron microscopy (EM) shows typical round morphology and size range of urinary EVs. B. Urinary EVs with 
multiple membrane layers (arrows) were seen occasionally. C.–D. Immuno-labelling of EV-markers CD59 and CD63 showed their presence on the urinary EVs by 
EM. E. The size distribution of the urinary EVs in the EM images indicated that most of the EVs were small, < 100 nm in diameter (N = 3, total of 425 EVs). F. Platelet 
EVs showed typical morphology and somewhat larger size than urinary EVs by EM. G. Western blotting of the samples from each step of the urinary EV isolation 
confirmed the enrichment of CD9, TSG101, CD59 and CD63 as well as the absence of cellular organelle proteins calnexin, TOMM20 and GM130 in the EVs. Equal 
quantities of protein were loaded from all urine-derived samples. Supernatant (sn).  
 
Nanoparticle Tracking Analysis 
Particle number and size distribution in the EV 
samples was analyzed with nanoparticle tracking 
analysis (NTA) instrument LM14C equipped with 
violet (405 nm, 70 mW) laser (Malvern Instruments 
Ltd., Malvern, UK) and sCMOS camera (Hamamatsu 
photonics K.K., Hamamatsu, Japan). Settings for uEV 
data acquisition by Nanosight software v2.3 (Malvern 
Instruments Ltd.) were: ambient temperature, camera 
level 12, autosettings off, polydispersity medium and 
reproducibility high with 40–100 particles per image. 
The used settings for pEVs were controlled 
temperature of 22.0°C and camera level 14 using 
Nanosight software 3.0 (Malvern Instruments Ltd.). 
EV samples were diluted with filtered (0.2 µm) PBS 
and three videos of 90 seconds were recorded from 
samples, mixing the samples manually between 
measurements. Data were analyzed with NanoSight 
NTA 3.0 software using detection threshold 5 and 
gain 10.  
Electron Microscopy 
Electron microcopy (EM) samples were prepared 
as described [27]. Briefly, EVs were loaded on 200 
mesh grids, fixed with 2% PFA, stained with 2% 
neutral uranyl acetate, embedded in methyl cellulose 
uranyl acetate mixture (1.8/0.4%) and viewed with 
Tecnai 12 (FEI Company, Eindhoven, The 
Netherland) at 80 kV. For immuno-EM, samples were 
blocked and antibodies diluted with 0.5% and 0.1% 
BSA, respectively, in 0.1 M NaPO4 buffer (pH 7.0). 
Samples were incubated with primary antibodies 
(CD63, CD59 as in Puhka et al. [27]) and 10 nm 





gold-conjugated anti-mouse secondary antibodies 
(BBI Solutions, Cardiff, UK) for 30–60 min at RT and 
washed extensively before staining and embedding. 
To quantify the size distribution of EVs, EV profiles 
were measured from randomly sampled images 
(maximum diameter, 100–400 profiles from each 
sample) of three independently processed uEV 
samples derived from different healthy donors and 
from a pEV sample derived from pooled platelets 
from four healthy donors.  
Ultra-Performance Liquid 
Chromatography-Tandem Mass Spectrometry 
EVs from 10–53 ml of urine and 5 ml of platelet 
concentrate (109–1011 particles), 100 µl urine filtrate 
(from 1.2 µm filtration step of EV isolation) and 1 x 107 
platelets were applied to analysis of 102 (uEVs and 
urine) or 111 (pEVs and platelets) polar metabolites 
(Table S2) using ultra performance liquid 
chromatography-tandem mass spectrometer 
(UPLC-MS-MS, ACQUITY UPLC® with Xevo TQ-S – 
tandem quadrupole mass spectrometer, Waters) as 
previously described [29]. Detailed methods are also 
found under Supplementary methods. A peak 
response giving signal to noise (S/N) ratio of < 3 was 
considered below the limit of detection. For 
calculation of average concentrations, concentrations 
below this limit were assigned as zeros. Lower limit of 
quantification was defined as the lowest 
concentration on calibration curve corresponding to 
S/N of > 6. 
Calculations, Database Searches and Data 
Analysis 
EV volumes were calculated using the NTA data 
i.e., using the EV diameters for calculating the sphere 
volumes in each size class, which were multiplied by 
the particle numbers in each size class. Subsequently, 
the EV volumes of all size classes were summed to 
yield the total volume of the EVs applied to the 
metabolomics analysis. Metabolite concentrations 
inside the EVs were calculated by dividing the mole 
amount of metabolites with the total volumes of EVs 
in the metabolomics samples. The metabolite 
concentrations of platelets were calculated similarly 
using the average platelet volume of 8 fl (normal 
range 7.2–11.7 fl in Demirin et al., 2011 [30]) and 1 x 107 
platelets/sample. The contribution of uEV-derived 
metabolites to urine was calculated by dividing the 
mole amount of individual metabolites in the control 
uEV samples with the urine volume from which the 
EVs were isolated and comparing this concentration 
value to the concentration of the same metabolites 
measured from the urine filtrates. Loss of EVs during 
isolation was not taken into account in these 
calculations. Human Metabolome Database (HMDB) 
and EVpedia (accessed 12.8.2016) were searched for 
reported EV-resident enzymes and transporters 
linked to the common EV metabolites. For assigning 
the subcellular localizations of the common EV 
metabolites, HMDB and Small Molecule Pathway 
Database (SMPDB) were used. The statistics module 
and metabolite set enrichment analysis through over 
representation analysis in the Metaboanalyst 3.0 
software were employed to analyze the metabolomics 
data. The MS-compound panel of 102 metabolites 
(Table S2) was used as a reference library and 
pathways with ≥ 2 metabolites present in all control 
samples of either EV type were included. For 
comparisons of population means, the input data was 
log-transformed, normalized to the EV-derived 
parameters or to concentrations of other metabolites 
from the same panel as indicated. When comparing 
two population means, differences between the 
groups were tested for statistical significance with 
non-parametric Wilcoxon rank test or student´s t-test 
with equal variance. For the comparisons of three 
population means, one-way ANOVA with Fischer’s 
LSD as the post-hoc analysis was used.  
Results 
Isolation and Validation of EV Samples for 
Metabolomics Analysis 
We isolated EVs with differential centrifugation 
from 10–53 ml of urine or 5 ml of platelet concentrate 
to include the EV populations with both exosomes 
and larger EVs (Fig. 1 and 2). Ultracentrifugation 
supernatants were carefully removed before and after 
the washing step to ascertain that the EV pellets 
would not contain any extra-vesicular urine or 
platelet concentrate supernatant-derived metabolites.  
To validate the quality of the EV isolation for the 
metabolomics study, EV samples were subjected to 
EM and western blotting (Fig. 1). Most uEVs detected 
with the EM were spheroids with a single membrane, 
but also some multi-membrane-layer EVs were found 
(Fig. 1A–D). Staining intensity of the EV membranes 
and contents varied. No mitochondria were observed. 
Immuno-EM with CD59- and CD63-antibodies 
showed a specific membrane staining (Fig. 1C and D). 
The size distribution analysis by EM showed that 83% 
of uEVs were under 100 nm in diameter (Fig. 1E) and 
the average diameter was 72 ± 39 nm (N = 425). 
Platelet EVs were morphologically similar but larger 
than uEVs (Fig. 1F): 61% of pEVs were under 100 nm 
in diameter (Fig. S1A) and the average diameter was 
136 ± 164 nm (N = 364). The proportion of > 200 nm 
EVs was 18% for pEVs vs. 1% for uEVs.  






Figure 2. Characterization of the urinary EV samples applied to metabolomics by western blotting and Nanoparticle tracking analysis. A. 
Western blotting of the urinary EV samples in the metabolomics study with EV-markers demonstrated significant variation in EV quantity from different donors. Two 
out of three samples from prostate cancer patients of Helsinki Urological Biobank project (HUB.1–3) obtained before prostatectomy (pre) contained more EVs than 
the samples from the same patients after prostatectomy (post) or from healthy controls. B. The urinary EV concentrations in these samples measured by nanoparticle 
tracking analysis and by quantification of CD9 band optical density (OD) from the western blot correlated well. C. Size distribution of the urinary EVs applied to 
metabolomics was obtained by nanoparticle tracking analysis showing that the EV sizes did not vary much between samples (N = 8).  
 
Western blotting showed that the uEV samples 
became enriched of typical uEV-markers CD9, CD63, 
CD59 and TSG101 compared to the samples from the 
earlier steps of the purification protocol (Fig. 1G). The 
same blots were also probed for cell organelle markers 
(calnexin, TOMM20 and GM130) demonstrating the 
absence of cellular debris from the uEVs. Similarly, 
western blotting of pEVs showed the presence of 
CD63 and TSG101 and minute amounts of CD9, as 
well as the absence of the mitochondrial marker 
TOMM20 (Fig. S1B).  
We also used western blotting and NTA to 
validate the individual uEV samples applied to the 
metabolomics i.e. the samples from three healthy 
controls and three Pca patients (HUB.1–3) from whom 
samples were obtained before and after prostatectomy 
(Table 1). However, all of the post-prostatectomy 
sample of HUB.1, where only 10 ml of urine was 
available for EV isolation, was applied to 
metabolomics and not analyzed by NTA and western 
blotting in order to save the EV material and increase 
the probability of successful metabolomics. Western 
blotting of CD9, CD63 and CD59 gave similar staining 
pattern, with the most intensive staining observed in 
HUB.1 and HUB.3 pre-prostatectomy samples (Fig. 
2A). The same samples also contained the highest EV 
concentrations by NTA (Table 1). Both the western 
blotting and NTA suggested highly varying 
concentrations of uEVs in the urine samples from 
different donors: the levels ranged one order of 
magnitude from 2.1 x 108 to 2.6 x 109 per ml of urine. 
Quantified values of CD9 from the western blotting 
correlated well with the NTA measurements yielding 
an R2 value of 0.966 (Fig. 2B). The size distributions of 
uEVs in the individual samples by NTA did not vary 
much (Fig. 2C). All samples contained over 85% 
(87–94%) of small, < 300 nm, EVs with a mean 
diameter of 182 ± 10 nm. NTA of the pEV samples 
applied to metabolomics analysis showed 1.7 x 1010 
EVs per ml of platelet concentrate and a mean 
diameter of 152 ± 6 nm (Fig. S1C). In conclusion, the 
quality control showed that our EV preparations 
contained EVs of sufficient purity in quantities that 
could be measured by NTA or by CD9 optical density.  
Approximately 1010 EVs are Sufficient for 
Targeted MS-Metabolomics Analysis 
We began our studies without a prior knowledge 
of the EV quantity required for the metabolite 
analyses. Because the EVs are small and we had 
limited amounts of patient samples, we presumed 
that a high sensitivity technique was needed for EV 
metabolomics. We thus chose an UPLC-MS-MS 
metabolite platform targeting a panel of 102 
metabolites from uEVs, and the same panel with nine 
additional metabolites (total 111) from pEVs (Table 





S2). These panels contained metabolites that could be 
measured with high sensitivity in reference to 
standards. Since the panels covered a range of 
biological compound classes, they served our purpose 
of exploring the metabolome of the EVs well. To 
determine the number of EVs required for 
metabolomics, we first analyzed serially diluted 
samples of pEVs. The majority of the analytes were 
above the detection limit when 1 x 1010 EVs were 
analyzed, but with 1 x 109 EVs, most metabolites 
remained below the detection limit (data not shown). 
The magnitude of the detected metabolite 
concentrations was comparable between the different 
UPLC-MS-MS runs when normalization of metabolite 
quantities was based on the EV volume (see Materials 
and Methods).  
Based on this pilot study, we used 1 x 1010 of the 
pooled pEVs for the metabolomics study. For uEVs, 
where the maximum amount of the available clinical 
sample material was always used, all samples 
contained approximately 1 x 1010 EVs (Table 1). 
Furthermore, the number of metabolites above the 
detection limit in the uEV samples did not depend on 
the amount of urine used for the EV isolation nor on 
the number of EVs obtained (Table 1). This suggested 
that all the uEV samples had sufficient number of EVs 
for metabolite analysis.  
In the uEV samples, 40–82 (39–80%) out of 102 
metabolites were above the detection limit and 32–55 
(31–54%) were above the quantification limit (Table 
1). There was no significant difference in the number 
of distinct metabolites detected between the study 
groups (healthy control, pre- or post-prostatectomy). 
In the pEV sample pool, 62 (56%) out of 111 
metabolites were detected and 41 (37%) were above 
the quantification limit. 
Main Metabolite Groups, Pathways and 
Concentrations in Urinary and Platelet EVs  
To identify typical EV-enriched metabolites, we 
first compared the profiles of the healthy control uEVs 
with the pEVs. Including 102 metabolites analyzed in 
both EV types, we found altogether 55 metabolites 
that could be quantified in the control uEVs, pEVs or 
both (Fig. 3A). The control uEVs contained 41 and 
pEVs 35 metabolites above the quantification limit, 
out of which 21 were equally present in both EV 
types, thus giving an > 50% overlap of each metabolite 
profile with the other (Fig. 3). Poorly detected (not 
present in all samples of either EV type) or totally 
missing metabolites also showed an > 70% overlap 
between uEVs and pEVs (data not shown). Only 11 
metabolites were specific to the uEVs and 5 to the 
pEVs (Fig. 3A).  
The commonly detected metabolites in the EV 
samples could be divided into five classes: 1) organic 
acids and their derivatives, 2) nucleotides, sugars and 
derivatives, 3) carnitines, 4) vitamin B/related 
metabolites and 5) amines (Fig. 3A). Organic acids, 
comprised particularly of amino acids, represented 
the largest individual group, but also purine 
metabolites in the nucleotide group, as well as fatty 
acyl carnitines in the carnitine group were common. 
To clarify, whether the EV metabolites in these groups 
were derived from particular metabolic pathways, we 
analyzed the lists of compounds quantified in all 
uEVs (healthy control samples) or pEVs separately 
with the metabolite set enrichment analysis in the 
Metaboanalyst using our MS-compound panel as a 
reference library [31]. When arranged according to the 
number of hits in the pathways, particularly urea 
cycle, arginine/proline and purine pathways, but also 
pathways for other amino acids and protein 
biosynthesis showed hits in both EV types (Fig. 3B). 
However, all members of these pathways present in 
the analysis panel were not in the quantifiable range 
in the EVs.  
We next investigated which metabolites were 
most concentrated in the EVs. In order to get an 
approximation of the intra-EV concentration range, 
we calculated the concentrations of the metabolites in 
the EVs by dividing the mole amount of metabolites 
with the total EV volumes in the samples (Table S3). 
The total volume of EVs ranged between 60–830 nl 
within the uEV preparations and was 372 nl in the 
pEVs. These calculations indicated that the intra-EV 
concentrations of the metabolites varied from sub 
micromolar up to > 10 mM in both uEVs and pEVs 
(Table S3). EVs from both sources were rich in 
D-Ribose 5-phosphate, the most abundant metabolite 
in pEVs and 3rd most abundant in uEVs, and other 
metabolites involved in nucleotide metabolism in 
mostly > 10 µM to mM range. Amino acid ornithine, 
with the highest concentration of metabolites in the 
uEVs and 15th highest in pEVs, and several other 
members of the urea cycle were present in > 50 µM to 
mM concentrations in the EVs. Ornithine serves also 
as a precursor for the biosynthesis of spermidine, a 
multifunctional polyamine that stabilizes nucleic 
acids and membranes, present in > 10 µM quantities 
in both EV types. In conclusion, our data indicated 
that the metabolite profiles of EVs from different 
sources contained similarities, but also distinct 
differences. The EVs carried a subset of metabolites 
from several pathways, with high intra-EV 
concentrations of some specific metabolites.  






Figure 3. Comparison of the metabolite content and pathways between urinary EVs and platelet EVs. A. Venn-diagram of the metabolites above the 
quantification limit in urinary and platelet EVs showed an > 50% overlap between the two EV types (derived from healthy individuals). The two EV types contained 
both EV-type specific (11 and 5 in urinary and platelet EVs, respectively) and common metabolites (21), as well as metabolites that were above the quantification limit 
in all samples of one EV type, but below this limit in one or more samples of the other (9 in each). Both EV types contained metabolites belonging to five different 
categories (highlighted with a color code in the image). B. Metabolite set enrichment analysis depicted the metabolic pathways that showed hits in both EV types 
(number of hits shown) and the total number of metabolites included in the metabolite panel from these pathways. platelet EVs (pEVs), urinary EVs (uEVs). 
“Intracellular signaling via adenosine…” continues with “receptor A2A/B and adenosine”.  





Metabolite Profiles of EVs and Matched EV 
Source Materials Show Overlap and 
Differences  
To confirm that we truly analyzed the 
metabolites within EVs and not in urine or platelets, 
we included the original matched urine samples (i.e. 
urine filtrate from the filtration step of the EV 
isolation), and platelet samples in the UPLC-MS-MS 
analysis. We found more metabolites in the urines 
than in the uEVs: 90–97 (88–95%) and 84–88 (82–86%) 
out of the 102 metabolites were above the detection 
and quantification limit in the urines, respectively 
(Table 1). Generally, the metabolite concentrations 
measured in this study (Table S4) agreed well with the 
concentrations reported in the HMDB for urine 
samples. Surprisingly, fewer metabolites reached the 
detection limit from platelets (51) than from pEVs 
(62). 
In order to get an insight of how much the 
metabolite profiles of EV and their matched source 
materials differ, we focused on the metabolites above 
the detection limit in control samples. Out of the 83 
metabolites above the detection limit in all three 
control urine samples, 36 (43%) were also detected in 
all control uEV samples (Fig. 4A). Only 6 metabolites 
were below the detection limit in the control urine 
samples including gamma-glutamylcysteine, a 
precursor of glutathione, which was found in all of the 
uEV samples. Since it was neither detected in pEVs or 
platelets, it was specific to uEVs. The uEVs, on the 
other hand, lacked 27 metabolites, 17 of which were 
present in the urines. Notably, among these, the 
average concentration of betaine in the urine was as 
high as 196 ± 86 µM. This ranks it the 13th highest in 
the list of common urine metabolites (Table S4).  
Platelets and pEVs showed a high overlap of the 
metabolite profiles (Fig. 4B). Out of 51 metabolites 
detected in all platelet samples, 47 (92%) were also 
detected in all pEVs. Interestingly, on the contrary to 
uEVs vs. urines, the pEVs contained many (11) 
metabolites that were not detected in platelets, 
whereas platelets contained just one compound, 
L-methionine, which was not detected in pEVs. 
Notably, the intra-EV concentration of D-ribose 
5-phosphate was as high as 68.8 mM, while it was not 
detected from platelets at all.  
To further ascertain that we analyzed 
EV-derived metabolites, we calculated the enrichment 
of metabolites inside the control uEVs and pEVs vs. 
their source samples (Table 2). Those metabolites that 
were present in all the EV samples, but not in all the 
source material samples, were assigned as enriched 
(enrichment up to > 500 x for those remaining sample 
pairs, where calculations could be made). Together, 
the nucleotide pathway metabolites were highly 
enriched: in addition to IMP and AMP (enriched), 
NAD+ (> 600 x) and D-ribose 5-phosphate (> 250 x), 
orotic acid (> 200 x) as well as niacinamide and 
adenosine (> 100 x) were enriched in the uEVs over 
urine. Two spermidine pathway metabolites, 
ornithine and spermidine, were enriched over 
800-fold in the uEVs relative to urine. Finally, 
gamma-glutamylcysteine, glutathione and glutamic 
acid (> 100 x) indicated an enrichment of the 
glutathione pathway metabolites in the uEVs over 
urine. In pEVs vs. platelets, the highest enrichment (> 
3–250 x) was seen in nucleotide, amino acid, carnitine 
and spermidine pathway metabolites. For example, 
D-Ribose 5-phosphate and orotic acid were only 
detected in pEVs, and adenosine (> 250 x), 
hypoxanthine (> 50 x) and NAD+ (> 10 x) were clearly 
enriched in the pEVs over platelets. Six carnitines 
were enriched over 3-fold in pEVs, while from the 
amino acids ornithine, histidine and valine were 
among the most enriched.  
Finally, we addressed the question, what was the 
contribution of uEV-derived metabolites to the total 
concentration of those metabolites observed in urine. 
For this, we calculated the molar amount of 
metabolites derived from the uEVs vs. urine 
individually. Apart from the metabolites that were 
not detected in one or more urine samples, the 
contribution of EVs to the urine metabolites was < 1% 
(data not shown). In conclusion, the metabolite 
profiles of the isolated EVs and the matched source 
materials were overlapping, but showed still clear 
qualitative and quantitative differences indicating 
that we successfully purified EVs and profiled their 
intra-EV metabolites.  
EVs Contain a Selection of Cytoplasmic 
Metabolites, which Match with the Reported 
Metabolic Enzymes and Transport Proteins in 
EVs 
EVs are generated via budding of the plasma 
membrane or multi-vesicular bodies, which could 
potentially create a miniature copy of the cytosolic 
metabolite contents of the secreting cell. To clarify, 
whether this was indeed the case, we searched for the 
subcellular localization of the EV metabolites from the 
HMDB and the SMPDB. The analysis indicated that 
95% and 85% of the metabolites in the quantifiable 
range had a cytoplasmic origin in the uEVs and pEVs, 
respectively (Fig. 5). However, over 60% of these 
metabolites could also be found in other subcellular 
localizations, especially in the mitochondria. 
Interestingly, cytosolic localization was also common 
for the metabolites totally missing from or poorly 
detected in the EVs suggesting that the metabolite 





content of EVs is not entirely similar to the 
cytoplasmic metabolome of cells.  
The presence of a selection of cytoplasmic 
metabolites led us to think that the EV metabolome 
could be modified by the metabolic enzymes in the 
EVs. We thus focused on the 21 common compounds 
found in all control uEV and pEV samples and 
searched for proteins linked to their metabolism or 
transport in the HMDB and EVpedia (Table 3). The 
list of enzymes and transporters identified in three or 
more EV-studies in EVpedia indicated that EVs 
contain an abundant selection of proteins linked to 
most of the 21 compounds. Particularly, many 
EV-proteins associated with AMP, glutamic acid, 
glutathione and aspartate metabolism. The result thus 
suggests that these metabolites are common in many 
EV types and could be transported or metabolized by 
the EV-resident proteins.  
Changes in EV Metabolite Contents in 
Prostate Cancer — Impact of the 
Normalization Methods 
The final question in our study was, whether the 
uEV-metabolites derived from typical biobank 
samples had the potential to reveal metabolite 
changes related to Pca. The patients enrolled in this 
initial study and their clinical characteristics are given 
in Tables 1 and S1. Patients HUB.1 and HUB.2 had a 
Gleason score (GS) 7 cancer with no apparent 
metastasis and patient HUB.3 had a GS 9 cancer that 
had spread to a lymph node. Both the tumor volume 
and the PSA concentration were highest in the GS 9 
patient, whose PSA also remained high after 
prostatectomy. Here, we focused on the metabolites 
that were altered in all pre-prostatectomy cancer 
samples relative to the healthy controls and the 
post-prostatectomy samples, where the 
prostate-derived tumor-EV load in urine could be 
presumed to be zero or significantly reduced. To 
detect a difference in the metabolite levels between 
samples, we needed a data normalization method that 
would take into account the varying amounts of 
samples available in the study. Since no standardized 
normalization method for the metabolomics data 
from the EVs existed, we tested several different 
options: normalization to EV volume, EV number, 
CD9 optical density, other metabolites, urine volume 
or urine creatinine.  
Normalization to EV volume, number and CD9 
optical density, which are all measures of EV quantity, 
yielded similar results (Fig. 6A, normalization to CD9 
shown, Fig. S2). We found four metabolites that had 
lower levels in the patient uEV samples before 
prostatectomy than in the control uEV samples and 
after prostatectomy (the EV or CD9 quantity of the 
post-prostatectomy sample of HUB.1 was not 
analyzed and this sample was therefore excluded 
here). These metabolites were adenosine, glucuronate, 
isobutyryl-L-carnitine, and D-ribose 5-phosphate. The 
levels of these metabolites in the pre-prostatectomy 
samples were 2.5–26.6-fold lower as compared to the 
combined group of post-prostatectomy and control 
samples (p < 0.05 for each comparison). Glucuronate 
showed the largest difference, with over 22-fold lower 
levels in pre-prostatectomy samples than in the other 
samples, with all three normalization methods. In 
addition to the four metabolites, the 
pre-prostatectomy uEV samples showed 2.3–22.8-fold 
lower levels of 1-methylhistamine, creatine, 
glutathione, propionylcarnitine, isovalerylcarnitine 
and NAD+ as compared to controls and 
post-prostatectomy samples when normalized to one 
or two EV-derived factors (all p < 0.05, data not 
shown).  
Normalization to other metabolites was based on 
the idea that the ratios of individual metabolites 
might change relative to each other in cancer vs. other 
groups reflecting the changed activity of metabolic 
pathways. Therefore, the metabolite concentrations 
were systematically normalized to each of the 28 
metabolites that were detected in all of the uEV 
samples. Most significant alterations are depicted in 
Figure 6B. Three of the previously identified 
metabolites showing low levels in the 
pre-prostatectomy uEV samples were also low here. 
First, the ratios of glucuronate to choline, hippuric 
acid and niacinamide were up to 26-fold lower in the 
pre-prostatectomy samples than in the other groups 
separately or combined (all p < 0.05). Second, the ratio 
of isobutyryl-L-carnitine to NAD+ or carnitine in the 
pre-prostatectomy samples was > 2.0-fold lower than 
in the other groups combined (p < 0.05 and 0.01, 
respectively). Third, D-ribose 5-phosphate to 
niacinamide ratio was equally lowered in 
pre-prostatectomy samples > 2.0-fold compared to 
other groups separately or combined (all p < 0.05). In 
addition, we found a lowered ratio of 
1-methylhistamine to choline (> 6.6 x) in the 
pre-prostatectomy samples compared to all the other 
groups (all p < 0.01). Normalization to choline 
revealed that the levels of several other metabolites 
were low in the pre-prostatectomy samples as well, 
with the ratios of guanidoacetic acid (> 7.8 x), taurine 
(> 3.5 x) and isovalerylcarnitine (> 3.7 x) to choline 
reaching statistical significance when compared to 
some of the other groups (all p < 0.05, data not 
shown).  






Figure 4. Comparison of the metabolite content in the EVs and their source materials. A. Venn-diagram of the metabolites above the detection limit in 
all urinary EVs (uEVs) from controls and the matched original urine samples showed overlap, but also sample type specific metabolites. Urine contained more unique 
compounds (17) than uEVs (1) indicating efficient purification of these from the uEV samples. B. Although platelet EVs (pEVs) and platelets had a highly overlapping 
metabolite content, the pEVs contained more unique metabolites (11) than platelets (1).  





Table 2. Enrichment of metabolites in the EVs vs. the matched EV source materials. The intra-EV concentrations of 
metabolites above the detection limit in all the control samples were compared to the concentrations in the original matched urine 
samples or platelets. This showed that some specific metabolites were enriched into EVs in high concentrations. Metabolites that were 
found in all the EV samples, but not in one or more of the source material samples were assigned as enriched directly. Platelet EVs (pEVs), 
urinary EVs (uEVs). 
 
 






Figure 5. Subcellular localization of the EV metabolites. Database searches using Human Metabolome Database and Small Molecule Pathway Database 
indicated that the subcellular localization of the metabolites found above quantification limit in the urinary and platelet EVs was mainly cytosolic. Many of the EV 
metabolites were assigned, in addition to cytosol, to other subcellular locations (the charts marked “+ other”) including mitochondria, ER, peroxisomes and 
lysosomes. Endoplasmic reticulum (ER), platelet EVs (pEVs), urinary EVs (uEVs). 
 
Table 3. Database analysis of enzymes and transporters associated with the common metabolites in the urinary and 
platelet EVs. A large number of enzymes and transporters in the Human Metabolome Database that linked to the 21 common 
metabolites in the urinary and platelet EVs resided in EVs according to the EVpedia. The EVpedia identification number shows the number 
of studies confirming the presence of the proteins in the EVs. Proteins not found from EVpedia (No), proteins not specified in the Human 
Metabolome Database (Ns). 
 
 






Figure 6. Most significant changes in the urinary EV metabolites in prostate cancer. A. Metabolite concentrations in the individual urinary EV samples 
were normalized to the CD9 optical density (OD) determined by western blotting, an EV-derived parameter. The analysis indicated lower levels of four metabolites 
in the pre-prostatectomy samples (pre) in comparison to post-prostatectomy (post) and healthy control samples. Pre- and post-prostatectomy samples from the 
same patients (HUB. 1–3) are connected with lines. B. Ratios between two metabolites indicated lower levels of glucuronate, isobutyryl-L-carnitine and D-ribose 
5-phosphate in the pre-prostatectomy samples as in A, but also changes in other metabolites. Statistical significance is indicated for the comparisons of 
pre-prostatectomy group to control and post-prostatectomy groups separately (small brackets) or to the combined control and post-prostatectomy group (large 
brackets). p < 0.05 (*), p < 0.01 (**). 





In contrast to the EV-derived factor and ratio 
normalizations, normalization to urine volume or 
creatinine did not produce any systematic differences 
that would distinguish the pre-prostatectomy uEV 
samples from the other study groups (data not 
shown). Our data thus suggests that normalization to 
EV-derived parameters or analysis of metabolite 
ratios would have the best potential to reveal 
cancer-related alterations in the EV metabolite 
profiles. 
Cancer-Related Changes in the Urine 
Metabolites Differ from the Changes in the 
Urinary EV Samples 
In addition to the uEV metabolomics, we 
assessed Pca-related changes in the matching urine 
samples. Changes in the pre-prostatectomy urine 
samples were different from those detected from the 
uEVs. When normalized to the urine creatinine 
content (measured from unpurified urine), glycine, 
histidine, proline and aminoisobutyric acid were 
lower in the pre-prostatectomy samples as compared 
to the combined group of control and 
post-prostatectomy samples (2.5–3.2 x, p < 0.05). 
When we normalized the results to the creatinine 
levels that were measured in the urine samples as part 
of the metabolite panel, histidine, aminoisobutyric 
acid and valine appeared lower in the 
pre-prostatectomy samples (2.0–3.4 x, p < 0.05). In 
conclusion, cancer-related changes in the uEV 
metabolites were larger and different than the ones 
detected by conventional analysis of urine alone.  
Discussion  
Metabolomic analysis of EVs is a new field of 
research that holds potential to reveal the status of 
cellular metabolism in a non-invasive way. It could 
unravel biomarkers for various diseases on its own or 
complement current assays of proteins and nucleic 
acids within EVs. Our work on the metabolite profiles 
of urinary and platelet EVs offers several new insights 
into EV contents and technical aspects of profiling the 
EVs for future biomarker research. 
Our data showed that the uEVs and pEVs had a 
common metabolic profile with amino acid, 
nucleotide, carnitine, vitamin B and amine 
metabolites. However, we also detected unique 
metabolites from each EV type, such as 
gamma-glutamyl-cysteine in the uEVs, which might 
be used to track the origin of the EVs. Most of the EV 
metabolites were derived from the cytosolic cellular 
pathways, fitting well with the current understanding 
of EV biogenesis, where portions of cytosol are 
engulfed within exosomes (via intraluminal vesicles) 
or microvesicles. Alternatively, metabolites might be 
specifically sorted into the EVs from cytosol or 
produced/altered within the EVs by enzymatic 
activity. In support of the latter, EVs are a rich source 
of metabolic enzymes [32, 33]. Also our analysis 
showed that the EVs did not contain all cytosolic 
metabolites or pathway members present in the 
analysis panel but rather a subset (Fig. 3B), which 
could be processed by numerous EV-residing 
enzymes/transporters (Table 3). Although our panel 
contained a good representation of metabolites from 
different metabolic pathways, it did not cover the 
whole metabolome and thus the analysis may have 
missed some pathways present in EVs. However, 
metabolic enzyme activity was further supported by 
the high local concentrations of some specific 
metabolites in the EVs over the cellular levels. For 
example, the comparison of the metabolite 
concentrations in the pEVs vs. platelets (Table 2) or 
the uEVs (Table S3) vs. cellular cytoplasmic 
concentrations reported in the HMDB [34] revealed an 
enormous (> 20 000-fold) enrichment of D-ribose 
5-phosphate in both EV types over the cellular 
concentrations. As indicated by the enzyme 
comparison from databases (Table 3), for example 
transketolase (TKT) or D-ribose 5-phosphate 
isomerase (RPIA) from the pentose phosphate 
pathway are good candidates that could catalyze the 
production of D-ribose 5-phosphate within EVs. 
D-Ribose 5-phosphate is a central product of the 
cytosolic pentose phosphate pathway and a key 
precursor in the phosphoribosylpyrophosphate, 
NAD+ and nucleotide biosynthesis. Increasing its 
availability in cells leads to accelerated purine 
synthesis [35]. Incidentally, our data indicated the 
enrichment of other metabolites from the purine 
pathway in the EVs as well.  
Another example of the EV-enriched metabolites 
were ornithine and spermidine. Their enrichment 
could be caused by the high activity of ornithine 
decarboxylase, the rate limiting enzyme of the 
polyamine synthesis pathway, and its regulators, in 
many secretory cell types [36]. Nevertheless, the 
question remains, whether EVs carry metabolites as a 
cargo in order to supply target cells with 
“off-the-shelf” metabolites as suggested by Zhao and 
others [8], or are some of them just passive products 
of intra-EV enzymatic activity. With the exception of 
some specific metabolites, our results suggest that the 
contribution of EV metabolites to the body fluid 
metabolome is generally low. Whether metabolites 
could be transferred to target cells more efficiently 
from EVs than from outside of EVs (in a soluble form), 
needs further study. Future explorations of the 
metabolomes of EVs vs. their source materials should 
help to identify other EV-enriched metabolites, the 





intra-cellular or communication pathways behind the 
enrichment and, finally, functions mediated by the 
EV-metabolites. Indeed, functions of the metabolites 
carried as EV cargo might be different than the 
functions of the same metabolites excreted in a soluble 
form. Nevertheless, the knowledge obtained here 
about metabolites enriched in the EVs over the source 
materials could already be used to direct future EV 
research or to redirect some of the metabolomics 
research on urine or platelets towards EVs.  
Since more specific Pca biomarkers are needed to 
replace PSA and biopsies for non-invasive 
detection/monitoring of clinically significant Pca [37], 
another part of our study focused on developing 
methods for EV sample preparation and data 
normalization that are suitable for EV metabolomics 
and future biomarker discovery. In our experiments, 
as little as 9 x 109 EVs or EVs from 10 ml of urine were 
enough to obtain a metabolite profile with the 
high-sensitivity targeted UPLC-MS-MS platform. In 
addition, our EV isolation protocol was able to 
remove several urine-derived soluble metabolites. For 
data normalization, we conducted an initial 
proof-of-concept study of Pca-derived changes in the 
uEV metabolite profiles. Normalization of the 
metabolomics data to the EV-derived parameters or 
by the ratio of metabolites led to the identification of 
metabolites with low levels in the pre-prostatectomy 
uEV samples. In contrast, traditional normalization 
parameters, creatinine and urine volume, did not 
reveal any systematic difference. Furthermore, the 
differences obtained with the uEV data were greater 
and different than the ones observed from the 
conventional analysis of the matched urine samples 
indicating the potential of EV-derived metabolomics 
for biomarker discovery. Future efforts could employ 
these techniques for EV biomarker discovery with a 
wider or more focused panel of metabolites and a 
higher number of patients. 
The metabolic changes typical for Pca could 
explain the low levels of the metabolites in the 
pre-prostatectomy uEVs. First, glucuronate, with the 
largest difference between the pre- and 
post-prostatectomy or healthy control samples, 
contributes to the pentose phosphate pathway 
necessary for nucleic acid synthesis. Since cancer cells 
have a higher demand for nucleic acids than normal 
cells, the increased usage could lead to reduced 
concentration of glucuronate in the EVs. In support, 
D-ribose 5-phosphate and adenosine from the purine 
pathway, were also low in the pre-prostatectomy uEV 
samples. Alternatively, less free glucuronate may be 
present in the cancer samples due to its heavy 
incorporation into proteoglycans, such as hyaluronan, 
or to toxic/waste substances in the detox metabolism 
through glucuronidation. Remarkably, it has been 
shown that hyaluronan synthesis is increased in Pca, 
promoting spontaneous metastasis [38] and also 
coating cancer-derived EVs [39].  
Second, the low levels of isobutyryl-L-carnitine 
in the pre-prostatectomy uEVs compared to 
post-prostatectomy and control uEVs suggests a 
balance shift towards beta-oxidation of fatty acids for 
energy production particularly, because the reduction 
was evident in relation to carnitine. Fatty-acids are 
combined with carnitines in order to enter 
mitochondria for beta-oxidation. More carnitine 
relative to isobutyryl-L-carnitine suggests that fatty 
acids are preferentially transported to mitochondria 
or used as building blocks for membrane biogenesis. 
Boost in beta-oxidation and lipid synthesis in Pca cells 
is supported by overexpression of several enzymes, 
such as AMACR, from these pathways [21].  
Third, the ratio of many metabolites to choline 
was low in the pre-prostatectomy uEVs compared to 
other groups, which suggests increased choline levels. 
Choline has important roles in the development of Pca 
and is heavily incorporated into prostate tumors, 
which is exploited in choline-PET scans [17]. 
Increased choline has also been detected in 
metabolomics studies profiling Pca tissue relative to 
benign tissue [19, 40]. In agreement with our results, 
Giskeødegård and others [40] also reported reduced 
levels of several purine nucleotides, taurine and a 
non-significant reduction of isobutyryl-L-carnitine in 
the cancer tissue. However, contrary to our EV data, 
they found adenosine to be increased indicating that 
the correlation of the metabolomics results from EVs 
and tissues may not be entirely straightforward.  
Some of our tested normalization factors such as 
CD9 optical density [41, 42] and choline concentration 
have been shown to increase in Pca. However, it is 
difficult to find a normalization factor that would not 
be affected by the changed metabolism in cancer or in 
other physiological conditions. From a different point 
of view, a ratio of decreasing and increasing 
parameters in cancer could be employed to detect 
changes in a more sensitive way than normalization to 
a stable parameter. Here, patient HUB.3, who had an 
aggressive cancer, had still high PSA in plasma after 
the prostatectomy, whereas our normalized uEV 
biomarker candidates returned towards the control 
level. This may be explained by the different amounts 
of primary tumor or metastatic site -derived material 
remaining in the blood and urine after prostatectomy. 
On the other hand, when normalized to 
uEV-parameters, the levels of D-ribose 5-phosphate 
and adenosine showed a relatively minor difference 
between the pre- and post-prostatectomy uEV 
samples of HUB.3 (Fig. 6A). Since these metabolites 





were generally present in high concentrations in the 
EVs and thus amenable to measurement from low 
sample amounts, one focus area of future Pca EV 
biomarker research could be the nucleic acid, 
particularly the purine pathway, metabolites.  
In conclusion, to our knowledge this is the first 
study of small polar metabolites from urine and 
platelet-derived EVs, which provides insights into the 
amounts of required material, the enriched 
metabolites and their cellular origin as well as data 
normalization procedures. We also obtained a core 
profile of metabolites from EVs against which 
differing metabolites from various EV types can be 
compared. Finally, this study provided leads to the 
changes in the metabolite profiles of EVs associated 
with Pca. Our study can serve as a basis for further 
studies of EV metabolites in different body fluids or in 
a larger group of Pca patients. Together, our findings 
suggest that EV metabolomics could offer a new 
non-invasive and high-throughput tool to monitor 
Pca or other diseases.  
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